Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: Results from a randomized, double-blind, placebo-controlled trial
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | TONIOLO, Ricardo Alexandre | |
dc.contributor.author | FERNANDES, Francy de Brito Ferreira | |
dc.contributor.author | SILVA, Michelle | |
dc.contributor.author | DIAS, Rodrigo da Silva | |
dc.contributor.author | LAFER, Beny | |
dc.date.accessioned | 2017-12-12T13:19:39Z | |
dc.date.available | 2017-12-12T13:19:39Z | |
dc.date.issued | 2017 | |
dc.description.abstract | Background: Depressive episodes and cognitive impairment are major causes of morbidity and dysfunction in individuals suffering from bipolar disorder (BD). Novel treatment approaches that target clinical and cognitive aspects of bipolar depression are needed, and research on pathophysiology suggests that mitochondrial modulators such as the nutraceutical creatine monohydrate might have a therapeutic role for this condition. Methods: Eighteen (N=18) patients with bipolar depression according to DSM-IV criteria who were enrollled in a 6-week, randomized, double-blind, placebo-controlled trial of creatine monohydrate 6 g daily as adjunctive therapy were submitted to neuropsychological assessments (Wisconsin Card Sorting Test, Digit Span subtest of the Wechsler Adult Intelligence Scale-Third Edition, Stroop Color-Word Test, Rey-Osterrieth complex figure test, FAS Verbal Fluency Test) at baseline and week 6. Results: There was a statistically significant difference between the treatment groups of the change on the total scores after 6 weeks in the verbal fluency test, with improvement in the group receiving adjunctive treatment with creatine. We did not find significant differences between the groups of the changes on other neuropsychological tests. Limitations: Small sample and lack of a control group of healthy subjects. Conclusions: Our trial, which was the first to investigate the cognitive effects of creatine monohydrate on bipolar depression, indicates that supplementation with this nutraceutical for 6 weeks is associated with improvement in verbal fluency tests in patients with this condition. | |
dc.description.index | MEDLINE | |
dc.description.sponsorship | NARSAD Independent Investigator Award from the Brain & Behavior Research Foundation [20202] | |
dc.description.sponsorship | Brazilian Federal research grants | |
dc.description.sponsorship | CNPq | |
dc.description.sponsorship | CAPES | |
dc.identifier.citation | JOURNAL OF AFFECTIVE DISORDERS, v.224, Special Issue, p.69-75, 2017 | |
dc.identifier.doi | 10.1016/j.jad.2016.11.029 | |
dc.identifier.eissn | 1573-2517 | |
dc.identifier.issn | 0165-0327 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/24342 | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE BV | |
dc.relation.ispartof | Journal of Affective Disorders | |
dc.rights | restrictedAccess | |
dc.rights.holder | Copyright ELSEVIER SCIENCE BV | |
dc.subject | Bipolar disorder | |
dc.subject | Depression | |
dc.subject | Cognition | |
dc.subject | Adjunctive therapy | |
dc.subject | Creatine monohydrate | |
dc.subject | Randomized controlled trial | |
dc.subject.other | magnetic-resonance-spectroscopy | |
dc.subject.other | human brain | |
dc.subject.other | 1st-degree relatives | |
dc.subject.other | oral supplementation | |
dc.subject.other | symptomatic status | |
dc.subject.other | euthymic patients | |
dc.subject.other | young-adults | |
dc.subject.other | disorder | |
dc.subject.other | metaanalysis | |
dc.subject.other | performance | |
dc.subject.wos | Clinical Neurology | |
dc.subject.wos | Psychiatry | |
dc.title | Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: Results from a randomized, double-blind, placebo-controlled trial | |
dc.type | article | |
dc.type.category | review | |
dc.type.version | publishedVersion | |
dspace.entity.type | Publication | |
hcfmusp.citation.scopus | 18 | |
hcfmusp.contributor.author-fmusphc | RICARDO ALEXANDRE TONIOLO | |
hcfmusp.contributor.author-fmusphc | FRANCY DE BRITO FERREIRA | |
hcfmusp.contributor.author-fmusphc | MICHELLE DA SILVA | |
hcfmusp.contributor.author-fmusphc | RODRIGO DA SILVA DIAS | |
hcfmusp.contributor.author-fmusphc | BENY LAFER | |
hcfmusp.description.beginpage | 69 | |
hcfmusp.description.endpage | 75 | |
hcfmusp.description.issue | Special Issue | |
hcfmusp.description.volume | 224 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.pubmed | 27890303 | |
hcfmusp.origem.scopus | 2-s2.0-85007135374 | |
hcfmusp.origem.wos | WOS:000413368300010 | |
hcfmusp.publisher.city | AMSTERDAM | |
hcfmusp.publisher.country | NETHERLANDS | |
hcfmusp.relation.reference | Arts B, 2008, PSYCHOL MED, V38, P771, DOI 10.1017/S0033291707001675 | |
hcfmusp.relation.reference | Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548 | |
hcfmusp.relation.reference | Balanza-Martinez V, 2010, EUR J PHARMACOL, V626, P87, DOI 10.1016/j.ejphar.2009.10.018 | |
hcfmusp.relation.reference | Bauer IE, 2015, J PSYCHIATR RES, V62, P115, DOI 10.1016/j.jpsychires.2015.01.008 | |
hcfmusp.relation.reference | Bauer M, 2015, INT J BIPOLAR DISORD, V3, DOI 10.1186/s40345-015-0029-x | |
hcfmusp.relation.reference | Bearden CE, 2001, BIPOLAR DISORD, V3, P106, DOI 10.1034/j.1399-5618.2001.030302.x | |
hcfmusp.relation.reference | Benkert O, 1997, J NERV MENT DIS, V185, P151, DOI 10.1097/00005053-199703000-00004 | |
hcfmusp.relation.reference | Berk M, 2011, NEUROSCI BIOBEHAV R, V35, P804, DOI 10.1016/j.neubiorev.2010.10.001 | |
hcfmusp.relation.reference | Bora E, 2009, J AFFECT DISORDERS, V113, P1, DOI 10.1016/j.jad.2008.06.009 | |
hcfmusp.relation.reference | Clay HB, 2011, INT J DEV NEUROSCI, V29, P311, DOI 10.1016/j.ijdevneu.2010.08.007 | |
hcfmusp.relation.reference | de Almeida KM, 2012, CNS NEUROSCI THER, V18, P160, DOI 10.1111/j.1755-5949.2011.00240.x | |
hcfmusp.relation.reference | Dechent P, 1999, AM J PHYSIOL-REG I, V277, pR698 | |
hcfmusp.relation.reference | Depp CA, 2016, PSYCHIAT CLIN N AM, V39, P95, DOI 10.1016/j.psc.2015.09.004 | |
hcfmusp.relation.reference | Depp CA, 2012, BIPOLAR DISORD, V14, P217, DOI 10.1111/j.1399-5618.2012.01011.x | |
hcfmusp.relation.reference | Depp CA, 2012, J AFFECT DISORDERS, V136, P812, DOI 10.1016/j.jad.2011.09.035 | |
hcfmusp.relation.reference | First M, 1996, STRUCTURED CLIN INTE | |
hcfmusp.relation.reference | Goodwin GM, 2008, EUR NEUROPSYCHOPHARM, V18, P787, DOI 10.1016/j.euroneuro.2008.07.005 | |
hcfmusp.relation.reference | Guy W., ECDEU ASSESSMENT MAN | |
hcfmusp.relation.reference | HAMILTON M, 1967, BRIT J SOC CLIN PSYC, V6, P278 | |
hcfmusp.relation.reference | Hammett ST, 2010, NEUROSCI LETT, V479, P201, DOI 10.1016/j.neulet.2010.05.054 | |
hcfmusp.relation.reference | Heaton R., 1981, WISCONSIN CARD SORTI | |
hcfmusp.relation.reference | Hu XP, 2012, NEUROIMAGE, V62, P1103, DOI 10.1016/j.neuroimage.2012.03.005 | |
hcfmusp.relation.reference | Jager R, 2011, AMINO ACIDS, V40, P1369, DOI 10.1007/s00726-011-0874-6 | |
hcfmusp.relation.reference | Judd LL, 2003, INT J NEUROPSYCHOPH, V6, P127, DOI 10.1017/S1461145703003341 | |
hcfmusp.relation.reference | Judd LL, 2002, ARCH GEN PSYCHIAT, V59, P530, DOI 10.1001/archpsyc.59.6.530 | |
hcfmusp.relation.reference | Kalra EK, 2003, AAPS PHARMSCI, V5 | |
hcfmusp.relation.reference | Kato T, 1996, J NEUROPSYCH CLIN N, V8, P417 | |
hcfmusp.relation.reference | Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937 | |
hcfmusp.relation.reference | Ke Y, 2000, PSYCHIAT RES-NEUROIM, V100, P169, DOI 10.1016/S0925-4927(00)00075-5 | |
hcfmusp.relation.reference | Kemp DE, 2014, J AFFECT DISORDERS, V169, pS34, DOI 10.1016/S0165-0327(14)70007-2 | |
hcfmusp.relation.reference | Kemp DE, 2010, BIPOLAR DISORD, V12, P404, DOI 10.1111/j.1399-5618.2010.00823.x | |
hcfmusp.relation.reference | Kurtz MM, 2009, NEUROPSYCHOLOGY, V23, P551, DOI 10.1037/a0016277 | |
hcfmusp.relation.reference | Ling J, 2009, BEHAV PHARMACOL, V20, P673, DOI 10.1097/FBP.0b013e3283323c2a | |
hcfmusp.relation.reference | Lyoo IK, 2003, PSYCHIAT RES-NEUROIM, V123, P87, DOI 10.1016/S0925-4927(03)00046-5 | |
hcfmusp.relation.reference | Lyoo IK, 2012, AM J PSYCHIAT, V169, P937, DOI 10.1176/appi.ajp.2012.12010009 | |
hcfmusp.relation.reference | McMorris T, 2006, PSYCHOPHARMACOLOGY, V185, P93, DOI 10.1007/s00213-005-0269-z | |
hcfmusp.relation.reference | MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382 | |
hcfmusp.relation.reference | Nierenberg AA, 2013, AUST NZ J PSYCHIAT, V47, P26, DOI 10.1177/0004867412449303 | |
hcfmusp.relation.reference | Nortje G, 2013, J AFFECT DISORDERS, V150, P192, DOI 10.1016/j.jad.2013.05.034 | |
hcfmusp.relation.reference | Ohtsuki S, 2002, J CEREBR BLOOD F MET, V22, P1327, DOI 10.1097/01.WCB.0000033966.83623.7D | |
hcfmusp.relation.reference | Post RM, 2010, J CLIN PSYCHIAT, V71, P1176, DOI 10.4088/JCP.08m04811yel | |
hcfmusp.relation.reference | Quraishi S, 2002, J AFFECT DISORDERS, V72, P209, DOI 10.1016/S0165-0327(02)00091-5 | |
hcfmusp.relation.reference | Rae C, 2003, DEV NEUROSCI-BASEL, V25, P324, DOI 10.1159/000073509 | |
hcfmusp.relation.reference | Rae C, 2003, P ROY SOC B-BIOL SCI, V270, P2147, DOI 10.1098/rspb.2003.2492 | |
hcfmusp.relation.reference | Rae CD, 2015, NEUROCHEM INT, V89, P249, DOI 10.1016/j.neuint.2015.08.010 | |
hcfmusp.relation.reference | Rakofsky JJ, 2011, CNS SPECTRUMS, V16, P11, DOI 10.1017/S1092852912000119 | |
hcfmusp.relation.reference | Rango M, 1997, MAGNET RESON MED, V38, P878, DOI 10.1002/mrm.1910380605 | |
hcfmusp.relation.reference | Rawson ES, 2008, PHYSIOL BEHAV, V95, P130, DOI 10.1016/j.physbeh.2008.05.009 | |
hcfmusp.relation.reference | Rey A, 1999, REVISAO TECNICA TRAD | |
hcfmusp.relation.reference | Robinson LJ, 2006, J AFFECT DISORDERS, V93, P105, DOI 10.1016/j.jad.2006.02.016 | |
hcfmusp.relation.reference | Alves CRR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076301 | |
hcfmusp.relation.reference | Rosa Adriane R, 2007, Clin Pract Epidemiol Ment Health, V3, P5, DOI 10.1186/1745-0179-3-5 | |
hcfmusp.relation.reference | SAPPEYMARINIER D, 1992, J CEREBR BLOOD F MET, V12, P584 | |
hcfmusp.relation.reference | Sarris J, 2016, AM J PSYCHIAT, V173, P575, DOI 10.1176/appi.ajp.2016.15091228 | |
hcfmusp.relation.reference | Sarris J, 2015, WORLD PSYCHIATRY, V14, P370, DOI 10.1002/wps.20223 | |
hcfmusp.relation.reference | Sarris J, 2011, BIPOLAR DISORD, V13, P454, DOI 10.1111/j.1399-5618.2011.00945.x | |
hcfmusp.relation.reference | Schlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004 | |
hcfmusp.relation.reference | Serretti A, 2013, J PSYCHOPHARMACOL, V27, P616, DOI 10.1177/0269881113485143 | |
hcfmusp.relation.reference | SILVER IA, 1994, J NEUROSCI, V14, P5068 | |
hcfmusp.relation.reference | Spreen O, 1998, COMPENDIUM NEUROPSYC, P213 | |
hcfmusp.relation.reference | Sylvia LG, 2011, J PSYCHIATR PRACT, V17, P224, DOI 10.1097/01.pra.0000398419.82362.32 | |
hcfmusp.relation.reference | Torres IJ, 2007, ACTA PSYCHIAT SCAND, V116, P17, DOI 10.1111/j.1600-0447.2007.01055.x | |
hcfmusp.relation.reference | Turner CE, 2015, J NEUROSCI, V35, P1773, DOI 10.1523/JNEUROSCI.3113-14.2015 | |
hcfmusp.relation.reference | WALLIMANN T, 1992, BIOCHEM J, V281, P21 | |
hcfmusp.relation.reference | Watanabe A, 2002, NEUROSCI RES, V42, P279, DOI 10.1016/S0168-0102(02)00007-X | |
hcfmusp.relation.reference | Wechsler D, 2011, TEX WASI 2 WECHSLER | |
hcfmusp.relation.reference | Wechsler D, 1997, WAIS 3 ADM SCOR MAN | |
hcfmusp.relation.reference | Wyss M, 2000, PHYSIOL REV, V80, P1107 | |
hcfmusp.relation.reference | YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429 | |
hcfmusp.relation.reference | Zahodne LB, 2014, J AM GERIATR SOC, V62, P130, DOI 10.1111/jgs.12600 | |
hcfmusp.scopus.lastupdate | 2024-05-17 | |
relation.isAuthorOfPublication | 3906b773-ecb4-4d21-9ae9-c3eff3886c6d | |
relation.isAuthorOfPublication | fc11bc70-f740-4f59-864b-2babc29d30d5 | |
relation.isAuthorOfPublication | f1f4521c-d352-4b1f-ad19-6f8c4df42fe7 | |
relation.isAuthorOfPublication | b37c7931-c261-4259-8959-eab55718fdd2 | |
relation.isAuthorOfPublication | 717693ba-66ff-4dac-9ac5-86d07eafb715 | |
relation.isAuthorOfPublication.latestForDiscovery | 3906b773-ecb4-4d21-9ae9-c3eff3886c6d |
Arquivos
Pacote Original
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- art_TONIOLO_Cognitive_effects_of_creatine_monohydrate_adjunctive_therapy_in_2017.PDF
- Tamanho:
- 253.38 KB
- Formato:
- Adobe Portable Document Format
- Descrição:
- publishedVersion(English)